Patient Education: Carfilzomib (Kyprolis) - Proteasome Inhibitor

Patient Education: Carfilzomib (Kyprolis) - Proteasome Inhibitor

Carfilzomib

NIH National cancer institute - cancer.gov site info

This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s): Kyprolis

FDA Approved: Yes

Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/carfilzomib

---

MedlinePlus Information

A lay language summary of important information about this drug that may include the following:

warnings about this drug,

what this drug is used for and how it is used,

what you should tell your doctor before using this drug,

what you should know about this drug before using it,

other drugs that may interact with this drug, and

possible side effects.

Learn more: